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Abstract
Background: Acetaminophen (APAP) overdose induces massive hepatocyte necrosis. Liver regeneration is a vital
process for survival after a toxic insult. Since hepatocytes are mostly in a quiescent state (G0), the regeneration
process requires the priming of hepatocytes by cytokines such as TNF-a and IL-6. Ringer’s lactate solution (RLS) has
been shown to increase serum TNF-a and IL-6 in patients and experimental animals; in addition, RLS also provides
lactate, which can be used as an alternative metabolic fuel to meet the higher energy demand by liver
regeneration. Therefore, we tested whether RLS therapy improves liver recovery after APAP overdose.
Methods: C57BL/6 male mice were intraperitoneally injected with a single dose of APAP (300 mg/kg dissolved in 1
mL sterile saline). Following 2 hrs of APAP challenge, the mice were given 1 mL RLS or Saline treatment every 12
hours for a total of 72 hours.
Results: 72 hrs after APAP challenge, compared to saline-treated group, RLS treatment significantly lowered serum
transaminases (ALT/AST) and improved liver recovery seen in histopathology. This beneficial effect was associated
with increased hepatic tissue TNF-a concentration, enhanced hepatic NF-B DNA binding and increased
expression of cell cycle protein cyclin D1, three important factors in liver regeneration.
Conclusion: RLS improves liver recovery from APAP hepatotoxicity.
Background
Acetaminophen toxicity is the leading cause of drug-
induced acute liver failure (ALF) in the US and Europe [1];
however the underlying mechanisms of APAP-induced
acute liver injury (ALI) are still not clear. The toxic
response to APAP is triggered by a highly reactive metabo-
lite, N-acetyl-p-benzoquinone imine (NAPQI), which
reacts with and depletes glutathione (GSH), after which, it
forms covalent adducts and initiates mitochondrial oxida-
tive stress [2,3]. This increases the membrane permeability
transition and causes the collapse of the mitochondrial
membrane potential, which resultantly diminishes the
mitochondrial capacity to synthesize ATP [4], and ATP
depletion leads to massive necrosis of the hepatocyte, a
characteristic feature of APAP hepatotoxicity [5].
Liver regeneration is a vital process for survival after a
toxic insult [6,7]. Regeneration ensures the replacement
of necrotic cells and the full recovery of organ function.
Since hepatocytes are mostly in a quiescent state (G0),
the regeneration process requires entry into the highly
regulated cell cycle [8]. The first step of this process is
the priming of hepatocytes by cytokines such as TNF-a
and IL-6 [9,10], which makes cells more responsive to
growth factors [8]. The exposure to growth factors such
as hepatocyte growth factor results in the expression of
cell cycle proteins [8]. The induction of cyclin D1 is the
most reliable marker for cell cycle (G 1 phase) progres-
sion in hepatocytes [8]. Once hepatocytes express cyclin
D1, they have passed the G1 restriction point and are
committed to DNA replication [8].
Many factors can influence liver regeneration. TNF-a
and IL-6 are important pro-regenerative cytokines, which
can prime hepatocytes to facilitate liver regeneration [8].
IL-8 and MIP-2, the CXC (CXC motif, the two N-terminal
cysteines of CXC chemokines are separated by one amino
acid, represented in this name with an “X”) pro-inflamma-
tory cytokines, are able to enhance hepatocyte regenera-
tion in acute liver injury induced by APAP even when the
treatment is delayed [11]. Currently, NF- B is thought to
play a major role in the initiation of liver regeneration
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any medium, provided the original work is properly cited.after cell or tissue loss (such as by hepatotectomy) [8]. In
addition, nutrients and metabolic status can also influence
regeneration, because APAP induces massive hepatocytes
necrosis. After the loss of a large number of parenchymal
cells, the metabolic work of surviving hepatocytes is
increased and more ATP is needed for maintaining home-
ostasis and regeneration [8].
Ringer’s lactate solution (RLS), a frequently used resusci-
tative fluid, has been shown to increase serum IL-6, IL-8
[12,13] and TNF-a [13,14] in patients and experimental
animals; in addition, RLS can provide lactate as an alterna-
tive metabolic fuel [15-21]. “Lactic acid” was thought to be
responsible for tissue damage, and as a consequence, lac-
tate is frequently considered to be a “toxic” compound.
These concepts are now being reexamined as metabolic
evidence has emerged in favor of lactate reassessment
[22,23]. Lactate provides a satisfactory alternative to glu-
cose as the primary energy in brain tissue during recovery
from hypoxia [24,25], and lactate infusion can improve the
recovery of neuron damage following brain injury [20].
Moreover, lactate improves cardiac efficiency during
shock, and it has recently been shown that lactate depriva-
tion during shock impairs heart metabolism [26]. Such evi-
dence indicates that lactate can be used as an energy
substrate and resuscitative fluid to improve liver recovery
from APAP-induced hepatotoxicity.
Based on this information, we hypothesize that RLS
might improve liver recovery in ALI induced by APAP. To
evaluate this idea, ALI was induced in mice by APAP i.p.
injection, and the mice were observed over a 72-h period.
Methods
Materials
All chemicals were purchased from Sigma-Aldrich Che-
mical Co. (St. Louis, MO, USA) unless otherwise noted.
Ethical considerations
This research protocol complied with the regulations
regarding the care and use of experimental animals pub-
lished by the National Institutes of Health and was
approved by the Institutional Animal Use and Care Com-
mittee of the University of Pittsburgh Medical School (Ref:
0609054A). Male C57BL/6 mice weighing 20-25 g (Jack-
son Laboratories, Bar Harbor, ME) were used and main-
tained at the University of Pittsburgh Animal Research
Center with a 12-hour light-dark cycle and free access to
standard laboratory food and water. The animals were
fasted over night prior to the experiments.
Animal experiments
In the first pilot experiment, 9 mice were intraperitone-
ally (i.p.) injected with a single dose of APAP (300 mg/kg
dissolved in 1 mL sterile saline) and randomized into the
RLS group (n = 3), the saline group (n = 3) and the
APAP alone group (n = 3). 3 mice injected with saline
not containing APAP served as a control group. Follow-
ing 2 hrs of APAP challenge, each group was empirically
given the following treatments every 12 hours for a total
of 72 hrs: 0.6 mL RLS for the RLS group, 0.6 mL saline
for the Saline group and 0.6 mL saline for the control
group (without APAP challenge), no further treatment
for APAP alone group. 72 hrs after APAP administration,
RLS-treated mice demonstrated significantly lower serum
AST than the saline treatment; the saline group had the
similar levels of serum ALT/AST as compared with the
APAP alone group, suggesting that saline therapy does
not have therapeutic effect on APAP-induced ALI. Since
no side effect was observed in the RLS group and serum
ALT was not markedly reduced by RLS therapy (with a
dosage of 0.6 mL), we increased RLS dose from 0.6 mL to
1 mL in the following experiments.
In the second pilot experiment, ALI was induced by a
single dose of APAP (300 mg/kg dissolved in 1 mL sterile
saline) administered by intraperitoneal (i.p.) injection.
APAP challenged mice were then randomized into the
RLS (n = 5) group and the Saline group (n = 5). 5 mice
injected with saline not containing APAP served as a
control group. 2 hrs after APAP administration, each
group was given the following treatments every 12 hours
for a total of 48 hrs: 1 mL RLS for the RLS group, 1 mL
saline for the Saline group and 1 mL saline for the con-
trol group (without APAP challenge). 48 hrs after APAP
challenge, compared to the saline therapy, RLS treatment
statistically decreased serum AST (p < 0.05), however,
RLS therapy did not statistically reduce serum ALT con-
centrations (p > 0.05), therefore, we extended the treat-
ment from 48 h to 72 h in the following experiments.
In the first experiment, ALI was induced by a single
dose of APAP (300 mg/kg dissolved in 1 mL sterile sal-
ine) administered by i.p. injection. APAP challenged mice
were then randomized into the RLS (n = 7) group and
the Saline group (n = 7). 6 mice injected with saline not
containing APAP served as a control group. 2 hrs after
APAP administration, each group was given the following
treatments every 12 hours for a total of 72 hrs: 1 mL RLS
for the RLS group, 1 mL saline for the Saline group and 1
mL saline for the control group (without APAP chal-
lenge). 72 hours after APAP injection, all surviving mice
(1 mouse died in each of RLS and Saline groups) in each
group were anesthetized with sodium pentobarbital (90
mg/kg i.p.), and the following procedures were per-
formed: 1) blood was aspirated from the heart for the
subsequent measurements of aspartate aminotransferase
(AST) and alanine aminotransferase (ALT); 2) left lobe of
liver was harvested for pathology (HE staining); 3) right
lobe of liver was harvested and frozen for following mea-
surements: hepatic NF-B DNA binding by EMSA; hepa-
tic tissue cyclin D1 expression by Western blot.
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were treated the same as above except the treatment
period was 24 hrs (n = 6 for each group).
Serum aminotransferase measurements
Serum levels of AST and ALT were measured at 37°C
with a commercially available kit (Sigma Diagnostic).
Histological analysis
Consecutive sections (5 μm) from paraffin-embedded liver
were prepared for hematoxylin-eosin staining. The percent
of necrosis was estimated by evaluating the number of
microscopic fields with necrosis compared with the entire
cross section. In general, necrosis was estimated at low
power (x100); questionable areas were evaluated at higher
magnification (x200 or x400). The pathologist evaluated
all histological sections in a blinded fashion. Inflammatory
cell infiltration results were scored semi-quantitatively by
averaging the number of inflammatory cells per micro-
scopic field at a magnification of 200×. Five fields were
evaluated per tissue sample, and six animals in each group
were examined.
Hepatic tissue TNF-a and IL-6 concentrations
To prepare protein extract, we homogenized murine tis-
sue samples with T-PER (Pierce, Rockford, IL), using a 1:
20 ratio of tissue-to-sample preparation reagent, as direc-
ted by the manufacturer’s instruction. The samples were
centrifuged at 10,000 g for 5 min to pellet tissue debris.
The supernatant was collected and frozen at -80°C. Pro-
tein concentration was determined using a commercially
available Bradford assay (Bio-Rad, Hercules, CA). The
supernatant was assayed for TNF-a and IL-6 using
ELISA kits from R&D Systems (Minneapolis, MN, USA)
according to the manufacturer’s instructions. The levels
were expressed as pg per mg of protein.
Serum TNF-a and IL-6 concentrations
Blood (1000 μL) was obtained by cardiac puncture and
the serum was collected and stored frozen at -80°C until
assayed for IL-6 and TNF-a using ELISA kits from R&D
Systems (Minneapolis, MN, USA) according to the man-
ufacturer’s instructions.
Tissue myeloperoxidase
Neutrophils infiltration was measured at 72 hours by deter-
mining myeloperoxidase (MPO) activity in liver tissue
homogenates as previously described [27] and was used as
an index of neutrophils infiltration in all groups. The MPO
levels were expressed as units per gram of tissue (U/g)
EMSA
NF-B activation was determined by EMSA, as pre-
viously described [28]. The gels were dried and exposed
to Biomax film (Kodak, Rochester, NY) at -70°C over-
night with use of an intensifying screen. Bands were
scanned at a NucleoVision imaging workstation and
quantified with GelExpert release 3.5. Data expressed as
Mean ± SEM (n = 6 per condition).
Western blot
Liver protein was extracted as previously described [29].
Equivalent amounts of protein were boiled in sample buf-
fer and separated on 7.5% pre-cast SDS-polyacrylamide
gels (Bio-Rad) and transferred to nylon membranes.
Membranes were then probed with a specific antibody
against cyclin D1 (Cell signaling Technology, Lexington,
KY) protein, visualized with an Enhanced Chemilumines-
cence substrate (ECL, Amersham Pharmacia Biotech)
and exposed to X-ray film according to the manufac-
turer’s instructions.
Proliferating cell nuclear antigen (PCNA) staining
Sections from mouse liver following APAP challenge were
prepared and processed for immunohistochemistry using
PCNA staining kits from Invitrogen (Camarillo, CA, USA)
according to the manufacturer’s instructions.
Statistical Methods
Results are presented as means ± SEM. Continuous data
were analyzed using student’s t-test or analysis of variance
followed by Fisher’s LSD test. P values < 0.05 were consid-
ered significant. Summary statistics are presented for den-
sitometry results from studies using western blot for cyclin
D1 expression but these results were not subjected to sta-
tistical analysis since the method employed was only semi-
quantitative (n = 6).
Results
Serum ALT/AST at 24 h, 48 h and 72 h time points
24 hrs after APAP injection, compared to saline treat-
ment group, RLS therapy did not decrease serum concen-
trations of ALT/AST (Figure 1A, B). 48 hrs after APAP
challenge, compared to the saline therapy, RLS treatment
significantly decreased serum AST (p < 0.05) but did not
statistically reduce serum ALT concentrations (p > 0.05,
Figure 1C, D). 72 hrs after APAP challenge, compared to
saline treatment group, RLS-treated mice demonstrated
significantly lower serum ALT and AST concentrations
(* indicates p < 0.05 vs. the control group; †indicates p <
0.05 vs. the saline group) (Figure 1E, F).
Liver histopathology
In histological evaluation 72 hrs after ALI induction,
compared to control animals, saline-treated mice demon-
strated 8.4 ± 1.3% necrotic area, mild regeneration and
extensive infiltration of inflammatory cells (260 ± 40 per
high power field, n = 6) in the centrilobular region. Loss
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found around hepatic central vein in the saline group. In
contrast, RLS treated mice demonstrated a few scattered
individual necrotic hepatocytes and evident regeneration
in the centrilobular region; the liver structure has
restored to nearly normal. Treatment with RLS did not
significantly reduce the number of inflammatory cells
(230 ± 35 per high power field, n = 6) (Figure 2).
Hepatic tissue TNF-a and IL-6
TNF-a and IL-6 are important pro-regenerative cytokines,
which can prime hepatocytes at early time point to facili-
tate liver regeneration, therefore, 24 h time point hepatic
tissue TNF-a and IL-6 concentrations were measured.
24 hrs after APAP injection, liver tissue TNF-a levels in
the control group and the saline group were undetectable,
hepatic tissue TNF- a concentration in the RLS group was
102.2 ± 14 pg/1 mg protein (n = 6). Hepatic tissue IL-6
concentration in the control group was 1800 ± 325 pg/1
mg protein, and this level was not significantly changed in
the RLS group or the Saline group (p > 0.05).
Serum TNF-a and IL-6 concentrations
24 hours after APAP injection, serum TNF-a concentra-
tions in the RLS and the saline groups remained the same
level as in the control group (10.3 ± 8 pg/mL, p > 0.05).
However, 72 hrs after APAP administration, compared to
saline treatment, RLS therapy significantly increased
Figure 1 Effect of treatment with RLS or Saline on ALT/AST in APAP-induced ALI model. Figure 1A and 1B: ALI was induced in C57Bl/6
male mice with a single dose of APAP (300 mg/kg) by i.p. injection. 2 hrs following APAP injection, the animals were treated with 1 mL RLS or
1 mL saline every 12 hrs. ALT and AST were measured 24 hrs after APAP injection (n = 6 survival mice for each group). Results are means ± SEM.
* indicates P < 0.05 versus control. Figure 1C and 1D: three separate groups of mice were used. ALI was induced the same as Figure 1A. 2 hrs
after APAP challenge, the animals were given the same treatment every 12 hrs for a total of 48 hrs. ALT and AST were measured 48 hrs after
APAP injection (n = 5 mice for each group). Figure 1E and 1F: three separate groups of mice were used. ALI was induced the same as Figure 1A
and the same treatment was given every 12 hrs for a total of 72 hrs. ALT and AST were measured 72 hrs after APAP injection (n = 6 survival
mice for each group). Results are means ± SEM. * indicates p < 0.05 vs. control; † indicates p < 0.05 vs. saline.
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control group; †indicates p < 0.05 vs. the saline group)
(Figure 3). Serum IL-6 concentration was undetectable in
each group at both 24 h and 72 h time points.
Hepatic tissue MPO level
Tissue MPO activity was determined as an index of neu-
trophils infiltration after APAP injection in liver. Liver
M P Oa c t i v i t yv a l u e sf o rt h ec o n t r o lg r o u pw e r e4 . 2±
0.22 U/g.
72 hours after ALI induction, these values significantly
increased to 8.6 ± 0.50 U/g in the saline group and 9.2 ±
0.3 U/g in the RLS group (p < 0.05), but there was no sta-
tistical difference between the saline group and the RLS
group (n = 6 for each group, data were shown as Mean ±
SEM, Figure 4).
Hepatic NF-B DNA binding
NF-B is a pleiotropic transcription factor whose activa-
tion has been linked to inflammatory and destructive
processes, as well as initiation of regenerative programs
in the injured liver. Blockade of HMGB1 protects against
ischemia-reperfusion (I/R)-induced liver injury; this pro-
tection is associated with increased NF-B DNA binding
activity [30]. Enhanced NF-B activation is seen in mice
that are protected from hepatic I/R following blockade of
the HMGB1 receptor for advanced glycation end
products (RAGE)[31]. Therefore, we examined the
impact of APAP on activation of NF-B at 72 hours after
APAP injection and tested the effect of RLS treatment.
There was a low basal level of NF- BD N Ab i n d i n gi n
the hepatic tissue samples in the control group. In the
saline group, there was a slight increase in NF- BD N A
binding. Treatment of mice after APAP challenge with
RLS clearly increased NF-B DNA binding relative to the
degree observed in mice treated with saline (Figure 5).
Hepatic cyclin D1 expression
The timely onset of tissue repair processes can limit
liver injury and promote regeneration of lost tissue mass
[7]. The induction of cyclin D1 is the most reliable mar-
ker for cell cycle (G1 phase) progression in hepatocytes
[8]. Western blot was performed using whole-cell
extracts prepared from liver tissue to assess expression
of cyclin D1 in mice subjected to ALI or the control
procedure. In Figure 6, cyclin D1 expression in the con-
trol group and saline group was minimal. In contrast,
cyclin D1 expression was clearly observed in RLS treated
animals at 72 h after APAP administration.
Hepatic PCNA expression
The hepatocyte proliferation was assessed by immuno-
histological staining for PCNA. The arrows showed
PCNA-positive nuclei. At 24 h time point, PCNA was
Figure 2 Effect of treatment with RLS or saline on pathology in mice with ALI. HE staining was assessed 72 h after induction of ALI (or
sham procedure). Method and treatment were the same as described in Figure 1C (n = 6 for each group). Typical picture is shown.
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saline-treated group (Figure 7B), RLS treated group
showed 15 ± 2 PCNA-positive nuclei per high power
field (Figure 7C) (n = 5 for each group). At 48 hours,
the number of labeled nuclei was significantly increased
in both saline (Figure 7D) and RLS (Figure 7E) groups,
although to a lesser extent in RLS-treated mice. After 48
h, the extent of hepatic PCNA expression, however,
Figure 3 Effect of treatment with RLS or saline on serum TNF-a in mice with ALI. Serum TNF-a was assessed 72 h h after induction of ALI
(or sham procedure). Results are means ± SEM (n = 6). * indicates p < 0.05 vs. control; † indicates p < 0.05 vs. saline.
Figure 4 Effect of treatment with RLS or saline on hepatic MPO activity in mice with ALI. Liver MPO was assessed 72 h h after induction
of ALI (or sham procedure). Results are means ± SEM (n = 6). * indicates P < 0.05 versus control.
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Page 6 of 10depended mainly on the extent of damage, because it
was significantly correlated with the area of hepatocyte
necrosis for each mouse; our result showed that the sal-
ine group had larger necrotic area (25.4 ± 3.7%) than
the RLS group (2.2 ± 0.3%), resultantly, the saline group
had a larger number of PCNA-positive cells than the
RLS group, our result was consistent with Javier
Vaquero’s report [32]. Additionally, clusters of PCNA-
positive cells were seen in the necrotic area, biliary duct
and blood vessels in both groups and the number of
these clustered cells could not be counted, and most of
the PCNA-positive cells were non-parenchyma cells,
therefore, the proliferation index could not be calcu-
lated. Similar results were seen at 72 h time point; only
the number of PCNA-positive nuclei in both groups was
less than that in the same treated groups at 48 h (data
not shown).
Discussion
The purpose of this study was to test the hypothesis that
RLS treatment improves liver recovery in ALI induced by
APAP. The major and the novel findings of this investiga-
tion are: (a) RLS-treated mice demonstrate decreased
serum ALT and AST and improved liver recovery 72 hrs
after APAP administration; (b) the beneficial effect is asso-
ciated with an augmented NF-BD N Ab i n d i n g ;a n d( c )
RLS-treated mice demonstrate significantly increased
expression of cell cycle protein cyclin D1 in liver tissue.
Figure 5 Effect of treatment with RLS or saline on NF-B DNA binding in nuclear extracts prepared from hepatic tissue samples from
mice with ALI. NF-B DNA binding was assessed 72 h h after induction of ALI (or sham procedure). Bands were scanned at a NucleoVision
imaging workstation and quantified with GelExpert release 3.5. Data expressed as Mean ± SEM (n = 6 per condition). * indicates P < 0.05 versus
Control; † indicates P < 0.05 versus Saline. The figure depicts results from six representative assays (n = 6). Typical gels are depicted
Figure 6 Effect of treatment with RLS or saline on the expression of cyclin D1 in the hepatic tissue. Western blot was performed using
hepatic extracts prepared from tissues obtained 72 hrs after APAP injection. The figure depicts results from six representative assays (n = 6).
Typical gels are depicted.
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Page 7 of 10In this study, after RLS treatment, hepatic inflamma-
tory cell infiltration was not reduced as seen in histo-
pathology; neutrophils infiltration was not decreased by
measuring MPO activity in total liver extracts. These
data indicate that improved liver recovery by RLS ther-
apy is not via changing hepatic inflammatory cells
infiltration.
To elucidate the molecular basis of liver recovery in
RLS-treated mice, we investigated its effect on the NF-B
signaling pathway because activation of NF-Bi sl i n k e d
strongly not only to the inflammatory response [30], but
also to liver regeneration [8]. In addition, NF- Bi sc u r -
rently thought to play a major role in the initiation of
liver regeneration after cell or tissue loss (such as partial
hepatectomy) [8,10]. NF- B activation also induces
increased expression of survival genes, including BCLXL
and A1 [33]. Our data suggested that RLS treatment is
associated with a beneficial response characterized by
activation of NF-B. Although NF-B activation modu-
lates inflammation [34], it is also known to protect hepa-
tocytes from cell death, and inhibition of NF-Ba f t e r
partial hepatectomy results in massive hepatocyte apop-
tosis, worsens liver injury and decreases survival [35].
Enhanced NF-B activation is also seen in mice that are
protected from hepatic I/R following blockade of the
receptor for advanced glycation end products [31]. There
is evidence suggesting that the impact of APAP toxicity
ensues, at least in part, by dramatic modulation of
inflammatory and/or regeneration programs [36]. It is
possible that in RLS treated mice subjected to APAP
overdose, enhanced NF-B activation diverts intracellular
pathways from those associated with inflammation and
cell death to mechanisms linked to recruitment and acti-
vation of pro-regenerative programs, therefore, activation
of NF-B by RLS treatment might facilitate regeneration
in this ALI induced by APAP.
Figure 7 Effect of treatment with RLS or saline on PCNA in mice with ALI. PCNA staining was assessed 24 h, 48 h after induction of ALI (or
sham procedure). Figure 7A, B and C, the method and treatment were the same as described in Figure 1A and 1B (n = 5 for each group). Figure
7D and 7E: three separate groups of mice were used. ALI was induced the same as Figure 1 A and B. 2 hrs after APAP challenge, the animals
were given the same treatment every 12 hrs for a total of 48 hrs. PCNA was detected 48 hrs after APAP injection (n = 5 for each group). Results
are means ± SEM. * indicates p < 0.05. Typical picture is shown.
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Page 8 of 10Massive hepatocyte necrosis is the predominant feature
of APAP-induced acute liver injury. Tissue repair is an
important determinant of final outcome of toxicant-
induced injury [7], and cyclin D1 is an important cell cycle
protein. In current investigation, our western blot data
showed that RLS treatment markedly increased the level
of cyclin D1 in the APAP challenged liver tissue. The
change in cyclin D1 expression was associated with
decreased serum AST and improved liver regeneration in
RLS -treated mice receiving APAP, suggesting that RLS
therapy likely facilitates cyclin D1-mediated regeneration
pathway, and the increased cyclin D1 expression might be
modulated by enhanced NF-B DNA binding [8].
RLS-treated mice demonstrated lower serum ALT/AST
and improved liver recovery at the 72 h time point. This
could be due to the increased pro-regenerative cytokine
TNF-a, at an early time point by RLS therapy and
increased TNF-a, might prime hepatocytes for regenera-
tion. RLS therapy also provides lactate as an alternative
metabolic fuel [16-21] to meet the increased energy
demand for regeneration after the massive necrosis
i n d u c e db yA P A P .T a k e nt o g e t h e r ,t h ei n c r e a s ei np r o -
regenerative cytokine and in fuel supply might hasten the
process of liver recovery from APAP overdose.
In this study, the number of PCNA positive cells was
large, and the vast majority of PCNA positive cells were
inflammatory cells, this is different from the other studies
which have shown hepatocytes at bordering area of necro-
sis express PCNA during injury progression [37,38]. There
are two possibilities for this phenomenon: (1) The specifi-
city and the sensitivity of the first antibody to PCNA might
markedly influence the results, because the other two stu-
dies used monoclonal antibody to PCNA from DakoCyto-
mation (Carpinteria, CA, USA) and Abcam, (Cambridge,
MA), our PCNA staining kit was purchased from Invitro-
gen (Camarillo, CA, USA). (2) Animal species might also
influence the results, because 24 hrs after APAP adminis-
tration, PCNA expression was apparent in B6C3F1 mice
[37] and B6J129 SVF2 mice [38], however, PCNA staining
was negative or occasional in C57/BL6 mice in our study
at 24 h time point, and our result was consistent with
another study [32] in which BrdU (5-bromo-2-deoxyuri-
dine) immunohistochemistry was performed to detect
hepatocyte regeneration in C57/BL6 mice.
Currently NAC, a glutathione precursor, is the anti-
dote for APAP overdose [39]. However, this antidotal
therapy is effective for early-presenting patients, and is
less effective for late-presenting patients [39,40], addi-
tional therapies are needed. Treatment with RLS would
serve as an adjuvant to NAC therapy. Further experi-
ments designed to compare the two therapies are
needed in the future.
Since RLS treatment is able to improve liver recovery
from APAP overdose in which massive necrosis of the
hepatocyte is a characteristic feature, it is possible that
RLS therapy may improve hepatic regeneration follow-
ing liver surgery (such as partial hepatectomy). Further
study is needed to confirm this idea in the future.
Conclusion
RLS treatment improves liver recovery after APAP over-
d o s ea n dR L Sm a yp r e s e n tan o v e lt h e r a p yt ot r e a t
APAP hepatotoxicity.
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